BIOCRYST PHARMACEUTICALS, INC. Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One
BIOCRYST PHARMACEUTICALS, INC. (BCRX) had Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One of $197.60 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Debt and Equity Securities
us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue · last filed 2026-08-05
- 2026-06-30: Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One $197.60M.
- 2026-03-31: Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One $66.81M.
- 2025-12-31: Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One $185.01M.
- 2025-09-30: Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One $128.79M.
| Period end | Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One |
|---|---|
| 2026-06-30 | $197.60M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $66.81M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $185.01M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $128.79M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $172.00M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $189.90M 10-Q · filed 2025-05-06 |
| 2024-12-31 | $216.14M 10-K · filed 2026-02-26 |
| 2024-09-30 | $233.17M 10-Q · filed 2024-11-05 |
| 2024-06-30 | $193.62M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $252.22M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $278.34M 10-K · filed 2025-02-25 |
| 2023-09-30 | $246.69M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $264.45M 10-Q · filed 2023-08-07 |
| 2023-03-31 | $243.02M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $119.54M 10-K · filed 2024-02-27 |
| 2022-09-30 | $179.96M 10-Q · filed 2022-11-04 |
| 2022-06-30 | $144.91M 10-Q · filed 2022-08-05 |
| 2022-03-31 | $47.96M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $3.21M 10-K · filed 2023-02-27 |
| 2020-12-31 | $28.24M 10-K · filed 2022-02-28 |
| 2020-09-30 | $46.83M 10-Q · filed 2020-11-06 |
| 2019-12-31 | $22.05M 10-Q · filed 2020-11-06 |
| 2019-09-30 | $38.53M 10-Q · filed 2019-11-08 |
| 2019-06-30 | $61.39M 10-Q · filed 2019-08-08 |
| 2019-03-31 | $72.75M 10-Q · filed 2019-05-09 |
| 2018-12-31 | $77.74M 10-K · filed 2020-03-13 |
| 2018-09-30 | $67.74M 10-Q · filed 2018-11-08 |
| 2018-06-30 | $53.64M 10-Q · filed 2018-08-09 |
| 2018-03-31 | $47.54M 10-Q · filed 2018-05-09 |
| 2017-12-31 | $64.11M 10-K · filed 2019-03-14 |
| 2017-09-30 | $43.85M 10-Q · filed 2017-11-08 |
| 2017-06-30 | $40.98M 10-Q · filed 2017-08-08 |
| 2017-03-31 | $23.52M 10-Q · filed 2017-05-08 |
| 2016-12-31 | $32.55M 10-K · filed 2018-03-12 |
| 2016-09-30 | $17.43M 10-Q · filed 2016-11-08 |
| 2016-06-30 | $27.08M 10-Q · filed 2016-08-08 |
| 2016-03-31 | $22.91M 10-Q · filed 2016-05-09 |
| 2015-12-31 | $22.66M 10-K · filed 2017-02-27 |
| 2015-09-30 | $23.70M 10-Q · filed 2015-11-06 |
| 2015-06-30 | $17.58M 10-Q · filed 2015-08-07 |
| 2015-03-31 | $19.16M 10-Q · filed 2015-05-08 |
| 2014-12-31 | $18.23M 10-K · filed 2016-02-26 |
| 2014-09-30 | $5.98M 10-Q · filed 2014-11-07 |
| 2014-06-30 | $10.59M 10-Q · filed 2014-08-08 |
| 2014-03-31 | $17.81M 10-Q · filed 2014-05-09 |
| 2013-12-31 | $16.89M 10-K · filed 2015-03-02 |
| 2013-09-30 | $16.54M 10-Q · filed 2013-11-08 |
| 2013-06-30 | $9.36M 10-Q · filed 2013-08-08 |
| 2013-03-31 | $13.46M 10-Q · filed 2013-05-09 |
| 2012-12-31 | $14.71M 10-K · filed 2014-03-10 |
| 2012-09-30 | $17.06M 10-Q · filed 2012-11-08 |
| 2012-06-30 | $12.96M 10-Q · filed 2012-08-08 |
| 2011-12-31 | $25.27M 10-K · filed 2013-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |